Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2006, 52, 47-58

https://doi.org/10.14712/fb2006052030047

Immunological Profiles of Patients with Chronic Myeloid Leukaemia. I. State before the Start of Treatment

Zuzana Humlová1,2, H. Klamová3, I. Janatková1, P. Šandová1, I. Šterzl2, E. Sobotková4, E. Hamšíková4, C. Haškovec5, M. Písačka3, P. Cetkovský3, K. Michalová6, E. Faber7, Z. Heřmanová8, M. Ordeltová8, K. Roubalová9, Z. Roth10, Vladimír Vonka4

1Department of Clinical Biochemistry and Laboratory Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
2Department of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, and the General Teaching Hospital, Prague, Czech Republic
3Clinical Department, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
4Department of Experimental Virology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
5Department of Molecular Biology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
6Department of Cytogenetics, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
7Department of Haemato-Oncology, The Teaching Hospital, Palacky University, Olomouc, Czech Republic
8Department of Immunology, The Teaching Hospital, Palacky University, Olomouc, Czech Republic
9Reference Laboratory for Herpesviruses, National Institute of Health, Prague, Czech Republic
10Department of Biostatistics, National Institute of Health, Prague, Czech Republic

Received May 2006
Accepted June 2006

In view of the increasing interest in the immunotherapy of CML it seems highly desirable to broaden the present knowledge on the immune reactivity of CML patients. A group of 24 patients and 24 healthy controls were studied for the total of 15 immunological parameters, including the prevalence of antibodies against human herpesviruses and papillomaviruses. To clearly discriminate between changes associated with the disease and those induced by the therapy, all patients were enrolled prior to the start of any anti-leukaemic therapy. Statistically significant differences between patients and controls were found in the levels of IgA, C4 component of complement, CRP and IL-6, the production of Th1 cytokines in stimulated CD3 cells and the E. coli stimulatory index. The analysis of the interrelationship between the results obtained in the individual patients presented some unexpected findings, such as the lack of correlation between the CRP and IL-6 levels. It will be the purpose of a follow-up to determine whether and how the immune status of the patients prior to the treatment correlates with their response to therapy and how the individual immunological profiles change in the course of the disease. These observations will be utilized in the future immunotherapeutic studies to constitute the vaccine- and placebo-treated groups.

Funding

This work was supported by grants NC/6957-3 and NR/9075-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic and by Research Project No. 000 273 3601, Institute of Haematology and Blood Transfusion, and by the League Against Cancer, Czech Republic.

References

50 live references